作者:
Cara,Haymaker [1]
;
Yi,Yang [2]
;
Junmei,Wang [3]
;
Qiang,Zou [3]
;
Anupama,Sahoo [3]
;
Andrei,Alekseev [3]
;
Divyendu,Singh [3]
;
Krit,Ritthipichai [1]
;
Yared,Hailemichael [1]
;
Oanh N,Hoang [3]
;
Hong,Qin [4]
;
Kimberly S,Schluns [3]
;
Tiejun,Wang [5]
;
Willem W,Overwijk [1]
;
Shao-Cong,Sun [3]
;
Chantale,Bernatchez [1]
;
Larry W,Kwak [4]
;
Sattva S,Neelapu [6]
;
Roza,Nurieva [7]
作者单位:
Department of Melanoma Medical Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
[1]
Department of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.;Department of Radiation Oncology, The Second Hospital of Jilin University, No. 218 Ziqiang St., Changchun City, Jilin Province, 130041, China.
[2]
Department of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
[3]
Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.;Toni Stephenson Lymphoma Center, City of Hope, 1500 East Duarte Rd., Duarte, CA, 91010, USA.
[4]
Department of Radiation Oncology, The Second Hospital of Jilin University, No. 218 Ziqiang St., Changchun City, Jilin Province, 130041, China.
[5]
Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
[6]
Department of Immunology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. rnurieva@mdanderson.org.
[7]
DOI
10.1038/s41467-017-00252-w
PMID
28798332
发布时间
2024-09-22